BioMarin Pharmaceutical traded at $112.20 this Friday February 3rd, decreasing $0.64 or 0.57 percent since the previous trading session. Looking back, over the last four weeks, BioMarin Pharmaceutical lost 4.94 percent. Over the last 12 months, its price rose by 26.59 percent. Looking ahead, we forecast BioMarin Pharmaceutical to be priced at 113.42 by the end of this quarter and at 102.62 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
112.20
Daily Change
-0.57%
Yearly
26.59%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Acadia Pharmaceuticals 19.83 -0.08 -0.40% -15.97%
Acorda Therapeutics 0.98 0.01 0.84% -48.10%
Agios Pharmaceuticals 30.20 0.02 0.07% 5.08%
Alnylam Pharmaceuticals 233.37 3.62 1.58% 60.48%
Amgen 245.17 -1.36 -0.55% 10.38%
Bayer 56.62 -0.18 -0.32% 7.60%
Biogen 283.63 -3.89 -1.35% 28.03%
Bluebird Bio 6.65 0.02 0.30% -2.35%
BioMarin Pharmaceutical 112.20 -0.64 -0.57% 26.59%
Gilead Sciences 84.50 3.11 3.82% 32.24%
Intercept Pharmaceuticals 19.02 -0.13 -0.68% 24.23%
Incyte Corp 83.61 -0.88 -1.04% 15.02%
Insmed 21.59 -0.14 -0.64% -2.00%
Ionis Pharmaceuticals 40.92 -0.28 -0.68% 29.90%
Moderna Inc 173.25 -3.10 -1.76% 6.28%
Neurocrine Biosciences 110.03 2.03 1.88% 35.61%
Puma Biotechnology 4.46 0.09 2.06% 84.30%
PTC Therapeutics 48.04 0.68 1.44% 14.14%
Ultragenyx Pharmaceutical 45.73 -1.61 -3.40% -33.36%
Regeneron Pharmaceuticals 783.13 31.93 4.25% 25.71%
Roche Holding 282.95 9.10 3.32% -18.04%
Seattle Genetics 138.00 -1.43 -1.03% 0.05%
Sangamo BioSciences 3.51 -0.16 -4.36% -36.87%
Sanofi 46.02 -1.22 -2.58% -11.64%
Sarepta Therapeutics 119.00 -1.25 -1.04% 62.77%
United Therapeutics 252.80 -6.68 -2.57% 25.40%
Vertex Pharmaceuticals 301.02 -2.76 -0.91% 24.41%

Indexes Price Day Year
USND 12007 -193.86 -1.59% -14.83%

BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.